Canadian approval for SpectRx:
This article was originally published in Clinica
SpectRx has received approval to market its BiliCheck non-invasive Bilirubin analyser in Canada. The hand-held device detects infant jaundice by shining a light on the infant's forehead. The light is then reflected back to the spectrometer inside the device and analysed for levels of bilirubin. Results are obtained immediately regardless of the infant's skin colour, gestational or post-natal age. Bilicheck uses the company's BiliCal calibration tips to perform automatic calibration before each measurement.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.